2026-2034年全球基於體學的臨床試驗市場規模、佔有率、趨勢和成長分析報告

全球基於體學的臨床試驗市場預計將從2025年的375.7億美元成長至2034年的773.9億美元，2026年至2034年的複合年成長率（CAGR）為8.36%。該市場快速擴張的原因在於精準醫療和先進基因組學研究在醫療保健領域的日益普及。以體學為基礎的臨床試驗利用基因組學、蛋白質組學、代謝體學及相關技術，開發個人化治療方案並提高藥物研發效率。慢性病盛行率的上升和對標靶治療需求的增加是推動市場成長的主要因素。定序和生物資訊學技術的進步也正在加速全球臨床研究的發展。

對藥物研發投入的增加以及對生物標記主導療法的日益關注是市場擴張的關鍵促進因素。醫療機構和生物技術公司正在利用體學技術對患者進行分層、分析治療反應並提高臨床試驗的成功率。研究機構和製藥公司之間合作的加強進一步促進了產業發展。此外，支持性的法規結構和對精準醫療舉措投入的增加也對全球市場的推廣產生了正面影響。

人工智慧 (AI) 和數據分析的持續進步為基於體學的臨床試驗市場帶來了非常積極的前景。機器學習和基因組數據分析的整合可望提高試驗效率並加速藥物研發進程。在醫療基礎設施改善和生物技術投資增加的推動下，新興市場的研究活動預計將會增加。隨著個人化醫療和標靶治療的不斷發展，預計該市場將在全球範圍內持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業的市場定位、產品系列、策略舉措和財務表現進行了詳細評估。這為深入了解競爭動態和主要參與者所採取的策略提供了寶貴的見解。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球基於體學的臨床試驗市場：按階段分類

• 市場分析、洞察與預測
• 第一階段
• 第二階段
• 第三階段
• 第四階段

第5章：全球基於體學的臨床試驗市場：依研究設計分類

• 市場分析、洞察與預測
• 干預研究
• 觀察性研究
• 擴展准入測試

第6章：全球以體學為基礎的臨床試驗市場：依適應症分類

• 市場分析、洞察與預測
• 自體免疫/炎症
• 疼痛管理
• 腫瘤學
• 中樞神經系統疾病
• 糖尿病
• 肥胖
• 心血管系統
• 其他

第7章 全球以體學為基礎的臨床試驗市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Parexel International（MA）Corporation
  • Thermo Fisher Scientific Inc
  • Charles River Laboratories
  • ICON Plc
  • SGS Societe Generale De Surveillance SA
  • Eli Lilly And Company
  • Pfizer Inc
  • Laboratory Corporation Of America
  • Novo Nordisk A/S
  • Rebus BiosystemsInc

The global omics-based clinical trials market size is expected to reach USD 77.39 Billion in 2034 from USD 37.57 Billion in 2025, growing at a CAGR of 8.36 during 2026-2034.This market is expanding rapidly due to increasing adoption of precision medicine and advanced genomic research in healthcare. Omics-based clinical trials use genomics, proteomics, metabolomics, and related technologies to develop personalized treatment approaches and improve drug development efficiency. Rising prevalence of chronic diseases and growing demand for targeted therapies are significantly driving market growth. Technological advancements in sequencing technologies and bioinformatics are also accelerating clinical research activities globally.

Increasing pharmaceutical research investments and rising focus on biomarker-driven therapies are major factors supporting market expansion. Healthcare organizations and biotechnology companies are using omics technologies to improve patient stratification, treatment response analysis, and clinical trial success rates. Growing collaboration between research institutions and pharmaceutical companies is further strengthening industry development. In addition, supportive regulatory frameworks and increasing funding for precision medicine initiatives are positively influencing market adoption worldwide.

Future prospects for the omics-based clinical trials market remain highly favorable due to continuous advancements in artificial intelligence and data analytics. Integration of machine learning with genomic data analysis is expected to improve trial efficiency and accelerate drug discovery processes. Emerging economies are projected to witness increased research activities due to improving healthcare infrastructure and biotechnology investments. As personalized healthcare and targeted therapeutics continue evolving, the market is anticipated to experience sustained global growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Interventional Studies
• Observational Studies
• Expanded Access Studies

By Indication

• Autoimmune / Inflammation
• Pain Management
• Oncology
• CNS Conditions
• Diabetes
• Obesity
• Cardiovascular
• Others

COMPANIES PROFILED

• Parexel International (MA) Corporation, Thermo Fisher Scientific Inc., Charles River Laboratories, ICON plc, SGS Societe Generale de Surveillance SA, Eli Lilly and Company, Pfizer Inc., Laboratory Corporation of America, Novo Nordisk A/S, Rebus Biosystems, Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: BY PHASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Phase
• 4.2. Phase I Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Phase II Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Phase III Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Phase IV Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: BY STUDY DESIGN 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Study Design
• 5.2. Interventional Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Observational Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Expanded Access Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Autoimmune / Inflammation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Pain Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. CNS Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Obesity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Phase
  • 7.2.2 By Study Design
  • 7.2.3 By Indication
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Phase
  • 7.3.2 By Study Design
  • 7.3.3 By Indication
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Phase
  • 7.4.2 By Study Design
  • 7.4.3 By Indication
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Phase
  • 7.5.2 By Study Design
  • 7.5.3 By Indication
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Phase
  • 7.6.2 By Study Design
  • 7.6.3 By Indication
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OMICS-BASED CLINICAL TRIALS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Parexel International (MA) Corporation
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 Charles River Laboratories
  • 9.2.4 ICON Plc
  • 9.2.5 SGS Societe Generale De Surveillance SA
  • 9.2.6 Eli Lilly And Company
  • 9.2.7 Pfizer Inc
  • 9.2.8 Laboratory Corporation Of America
  • 9.2.9 Novo Nordisk A/S
  • 9.2.10 Rebus BiosystemsInc